Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Journal of Autoimmunity2020Vol. 111, pp. 102452–102452
Citations Over TimeTop 1% of 2020 papers
Related Papers
- → COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients(2020)78 cited
- → Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence(2021)58 cited
- → Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19(2020)11 cited
- → The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).(2020)